Mon panier

Human VEGF165 Protein, His Tag, low endotoxin (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
VE5-H5248-50ug
$390.00
VE5-H5248-1mg (500ug X 2)
$3660.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF

  • Source

    Human VEGF165, His Tag (VE5-H5248) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4). In the region Ala 27 - Arg 191, the amino acid sequences of VEGF165 from Human, Cynomolgus and Rhesus macaque are identical.

    Predicted N-terminus: His

    Request for sequence

  • Molecular Characterization

    VEGF165 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 21.1 kDa. The protein migrates as 27-28 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    The protein is designed as a dimer.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    VEGF165 SDS-PAGE

    Human VEGF165, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    VEGF165 SEC-MALS

    The purity of Human VEGF165, His Tag (Cat. No. VE5-H5248) is more than 95% and the molecular weight of this protein is around 42-60 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     VEGF165 ELISA

    Immobilized Human VEGF R1&VEGF R2, Fc Tag at 2 μg/mL (100 μL/well) can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with a linear range of 0.004-0.063 μg/mL (QC tested).

    Protocol
  • Bioactivity-TR-FRET

     VEGF165 TR-FRET

    In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-His Tag Antibody, Rabbit IgG FA-Labeled (for TR-FRET) (Cat. No. FRT-TA11) is used as the Acceptor. Human VEGF165, His Tag (Cat. No. VE5-H5248), at 1.25 ng/well and Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1), at 1.25 ng/well, can bind to the Ivonescimab with a linear detection range of 2-0.002 μg/mL (Routinely tested).

  • Bridging ELISA

     VEGF165 BRIDGING ELISA

    Validated with Bispecific Antibody.
    Immobilized Human VEGF165 Protein, His Tag, low endotoxin (MALS verified) (Cat. No. VE5-H5248) at 1 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Cynomolgus PD-1 / PDCD1 Protein, Fc,Avitag™ (MALS verified) (Cat. No. PD1-C82F7) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.244 ng/mL (Routinely tested).

  •  VEGF165 BRIDGING ELISA

    Validated with Bispecific Antibody.
    Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 1 μg/mL, add increasing concentrations of Pumitamig and then add Biotinylated Human PD-L1, Avitag,His Tag (Cat. No. PD1-H82E5) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.31 ng/mL (Routinely tested).

  • Bioactivity-SPR

     VEGF165 SPR

    Avastin (Bevacizumab) captured on CM5 chip via ant-human IgG Fc antibodies surface, can bind Human VEGF165 Protein, His Tag (Cat. No. VE5-H5248) with an affinity constant of 1.03 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     VEGF165 BLI

    Loaded Human NRP1, Fc Tag (Cat. No. NR1-H5252) on Protein A Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 24.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  VEGF165 BLI

    Loaded Biotinylated Human VEGF R1, His,Avitag (Cat. No. VE1-H82E3) on SA Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 0.236 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Vascular endothelial growth factor A

  • Catégorie:

  • Nombre de médicaments répertoriés:

    54 Détails

  • Nombre de médicaments cliniques:

    61 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte